About Sellas

SELLAS Life Sciences is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.

SELLAS’ lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the top priority among cancer antigens for immunotherapy. Traditional approaches have not yet been proven to successfully address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies. SELLAS has been working with MSKCC since 2014, and MSKCC is also a current shareholder of SELLAS.

SELLAS plans to initiate a pivotal Phase 3 study in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM), pending funding availability. SELLAS is currently conducting Phase 1 and Phase 2 studies in multiple myeloma (MM) and ovarian cancer (combination with nivolumab (Opdivo®) and will advance additional studies into the clinic. Phase 2 data in AML and MPM have shown positive survival trends, with median overall survival (OS) in AML of 67.6 months vs. ~12-15 months for best standard treatment (in patients of all ages) and median OS in MPM of 22.8 months vs. 18.3 months in the control arm. Further recent data in MM has shown an 88% overall survival rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation. The US FDA granted Orphan Designations and Fast Track Designations for SELLAS' WT1 therapy, galinpepimut-S, for AML and MPM and the EMA granted Orphan Designation for AML and MPM.

Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by a well-tolerated safety profile not yet been proven to be found in standard of care therapies.

SELLAS was founded in 2012 and its headquarters are in New York City.

Management

Portrait

Angelos M. Stergiou, MD, ScD h.c. , President & Chief Executive Officer

Dr. Angelos M. Stergiou, founder, President & Chief Executive Officer of SELLAS Life Sciences Group, Inc. has held international positions of increasing responsibility in pharmaceuticals and biotechnology companies over the past 15 years, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, Anavex Life Sciences. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas.

Dr. Stergiou has held specific roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).

Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including Central Nervous System, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan.

Dr. Stergiou was part of the joint steering and oversight committee in the license deal of Paion’s desmoteplase drug with Forest Labs and part of senior management of Accentia Biopharmaceuticals and Biovest International. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology.

Dr. Stergiou holds a Doctor of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College and US American Institute of Medicine, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry.

Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. He is a frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and lectured at post-secondary institutions including Columbia University, and numerous European universities.

He is fluent in English, German and Greek.

Portrait

Gene Mack , Chief Financial Officer

Gene has over 20 years of experience in the life sciences sector spanning clinical research, financing, investing, corporate strategy and business development with private and public companies. Prior to joining Sellas, Gene was a consultant for a number of private and public biotechnology and pharmaceutical companies providing advisory and support for raising capital and business development transactions as well as implementing and managing all aspects of corporate finance, accounting, SEC reporting, legal affairs, treasury and investor/public relations. Formerly Gene was Senior Vice President and Chief Financial Officer of privately held Ascendia Pharmaceuticals from 2015 to 2017. Prior to Ascendia, Gene was Senior Director, Corporate Finance for Edge Therapeutics from 2013 to 2015 From 2000 to 2013 Gene was a senior publishing analyst covering the life sciences sector at various banking institutions including Gruntal & Co, Lazard, and HSBC. Prior to his tenure on Wall Street, Gene completed research in biochemistry, at Cornell University Medical College and clinical neurology at Columbia University College of Physicians and Surgeons where he was part of a team investigating less invasive treatments for malignant gliomas and cerebrovascular disease including aneurysms, arteriovenous malformations and stroke. Gene received both his BS in Biochemistry and MBA in Finance from Fordham University.

Portrait

Nicholas J. Sarlis, MD, PhD, FACP , Chief Medical Officer & Senior VP

Dr. Nicholas J. (Nick) Sarlis is the Chief Medical Officer and Senior VP of SELLAS Life Science Group, Ltd,, and an experienced clinician as well as recognized expert in the global pharmaceutical market with a focus in oncology and hematology.

As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat , the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the successive launches of ruxolitinib (Jakafi®) – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products in both the United States and the European Union. He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the University of London. Dr. Sarlis is board certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center.

Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS).

Portrait

Barbara Wood , Executive Vice President, General Counsel and Corporate Secretary

Barbara Wood is Executive Vice President, General Counsel and Corporate Secretary. . Ms. Wood has been practicing law for over 30 years. She was previously Senior Vice President, General Counsel and Corporate Secretary of Ophthotech Corporation. Prior to joining Ophthotech, she spent 10 years at OSI Pharmaceuticals, Inc., where she was Senior Vice President, General Counsel and Secretary.

Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School where she was a Harlan Fiske Stone Scholar and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.

Board of Directors

Jane Wasman

Ms. Wasman has been President, International & General Counsel and Corporate Secretary of Acorda Therapeutics, Inc., or Acorda, a publicly traded biopharmaceutical company, since October 2012, managing its International, Legal, Quality, IP and Compliance functions. From January 2012 until October 2012, she was Acorda’s Chief, Strategic Development, General Counsel and Corporate Secretary, and from May 2004 until January 2012, she was Acorda’s Executive Vice President, General Counsel and Corporate Secretary. Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S. and international leadership positions, including Staff Vice President and Associate General Counsel. Ms. Wasman earned a J.D. from Harvard Law School and her undergraduate degree magna cum laude from Princeton University. She has been a member of the board of directors and of the executive committee of the board of the New York Biotechnology Association since 2007.

Stephen F. Ghiglieri

Mr. Ghiglieri is currently serving as Galena’s Interim Chief Executive Officer and Chief Financial Officer. Mr. Ghiglieri joined Galena in November 2016 as Chief Financial Officer. In February 2017, his responsibilities increased as he was appointed Interim Chief Executive Officer. Prior to Galena, Mr. Ghiglieri served as Chief Financial Officer of MedData Inc., a private equity backed healthcare services company that was sold to Mednax, a publicly traded national medical group from 2013 until April 2016. Previously, he spent nearly 10 years at NeurogesX from October 2003 until June 2013, ending his tenure as its Executive Vice President, Chief Operating Officer and Chief Financial Officer. Prior to that, he served as the Chief Financial Officer of Hansen Medical, Inc., a medical device company. He also held senior level finance positions at two other healthcare companies: Oacis Healthcare Systems, Inc., and Oclassen Pharmaceuticals, Inc. Additionally, Mr. Ghiglieri was also the Chief Financial Officer and Corporate Secretary for two technology software companies: Avolent, Inc., and Andromedia, Inc. Mr. Ghiglieri began his career as an audit manager of PricewaterhouseCoopers, LLP. He received a B.S. in Business Administration from California State University, Hayward where he graduated Magna Cum Laude. Mr. Ghiglieri is also a Certified Public Accountant (inactive).

David A. Scheinberg, M.D., Ph.D.

Dr. Scheinberg is currently Vincent Astor Chair, and Chairman, Molecular Pharmacology, Sloan Kettering Institute. He also founded and chairs the Center for Experimental Therapeutics at MSK, where he spearheaded the discovery and early clinical development of GPS, and founded and was chair of the Nanotechnology Center from 2010 to 2014. He is additionally Professor of Medicine and Pharmacology and co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSK. Dr. Scheinberg is also an attending physician in the Department of Medicine, Leukemia Service and Hematology Laboratory Service/Department of Clinical Laboratories at Memorial Hospital. Dr. Scheinberg is an advisor to charitable foundations and cancer centers and sits on the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a biotechnology company. Dr. Scheinberg has also served on SELLAS’ Scientific Advisory Board since 2015. From 2010-2016 he served on the board of directors of Contrafect Corporation, a publicly traded clinical-stage biotechnology company. Dr. Scheinberg holds an M.D. and a Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University School of Medicine. Dr. Scheinberg earned his undergraduate degree in Biology from Cornell University.

Robert L. Van Nostrand

Mr. Van Nostrand is currently on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a biotechnology company, Enumeral Biomedical Corporation (OTCMKTS: ENUM), a biotechnology company, Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company, Yield10 Bioscience, Inc. (NASDAQ: YTEN), formerly Metabolix, Inc., a bio agricultural company, and the Biomedical Research Alliance of New York, a private company providing clinical trial services. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc., a pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Laboratories, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, a private biotechnology company, from July 2007 to September 2008 when the company was acquired. Between 1986 and 2007, Mr. Van Nostrand held various executive and other management positions, including Chief Compliance Officer and Chief Financial Officer, at OSI Therapeutics, Inc., or OSI. Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. Mr. Van Nostrand is also on the board of New York Biotechnology Association and was the former chairman, and is on the Foundation Board of Farmingdale University. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University, New York and completed advanced management studies at the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

John Varian

Mr. Varian served as Chief Executive Officer of XOMA Corporation, or XOMA, from August 2011 through December 2016 and served as a member of the Board of Directors of XOMA from December 2008 through May 2017. Mr. Varian currently serves as a member of Versartis, Inc.’s (NASDAQ: VSAR) Board of Directors, a position he has held since March 2014. Mr. Varian previously served as Chief Operating Officer of ARYx Therapeutics, Inc. from December 2003 through August 2011. Beginning in May 2000, Mr. Varian was Chief Financial Officer of Genset S.A. in Paris France, where he was a key member of the team negotiating Genset’s sale to Serono S.A. in 2002. From 1998 to 2000, Mr. Varian served as Senior Vice President, Finance and Administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation’s Chief Financial Officer from 1997 until 1998. From 1991 until 1997, Mr. Varian served as the VP Finance and Chief Financial Officer of Anergen Inc. Mr. Varian was an Audit Principal / Senior Manager at Ernst & Young LLP from 1987 until 1991 where he focused on life sciences. Mr. Varian was also a founding committee member of Bay Bio and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian holds a B.B.A. from Western Michigan University. SELLAS believes Mr. Varian’s significant experience working with biopharmaceutical companies, with a specific focus on financing, corporate financial management and related matters, qualifies him to serve on the continuing company’s board of directors.

Angelos M. Stergiou, M.D., Sc.D. h.c.

Dr. Stergiou has served as SELLAS’ Chief Executive Officer since founding SELLAS in 2012 and has also served as a director since that time, both as Chairman from 2012 to July 2016, and as Vice Chairman since July 2016. Dr. Stergiou also co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company. Dr. Stergiou served on the joint steering and oversight committee of PAION AG with Forest Labs in 2003-2004 as it relates to the desmoteplase technology and its clinical development program, had a senior management role, Vice President and Head of Drug Development at Accentia Biopharmaceuticals, Inc. from 2004 to 2008 and also served in the same capacity as well as Chief Medical Officer at its subsidiary Biovest International, Inc. during the same time. While at Biovest International, Inc., Dr. Stergiou led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, which was presented at the American Society of Clinical Oncology plenary session in 2009. Dr. Stergiou holds an M.D. from the U.S. American Institute of Medicine and a Sc.D. h.c. from Kentucky Wesleyan College and received his undergraduate degree in pre-medicine, biology and chemistry from Kentucky Wesleyan College. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College, a Fellow of the Royal Society of Medicine, an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals.

Scientific Advisory Board

David A.Scheinberg

David A.Scheinberg,MD, PHD

Alexander

Alexander M.M. Eggermont, MD, PHD

Guenther Koehne

Guenther Koehne,MD, PhD

Larry W. Kwak

Larry W. Kwak,MD, PHD

Sattva Neelapu

Sattva Neelapu,MD, PHD

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz, MD, PHD

Jeffrey Weber

Jeffrey Weber, MD, PHD

Jedd D. Wolchok

Jedd D. Wolchok,MD, PhD

Dr. Scheinberg is currently Vincent Astor Chair, and Chairman, Molecular Pharmacology, Sloan Kettering Institute. He also founded and chairs the Center for Experimental Therapeutics at MSK, where he spearheaded the discovery and early clinical development of GPS, and founded and was chair of the Nanotechnology Center from 2010 to 2014. He is additionally Professor of Medicine and Pharmacology and co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSK. Dr. Scheinberg is also an attending physician in the Department of Medicine, Leukemia Service and Hematology Laboratory Service/Department of Clinical Laboratories at Memorial Hospital. Dr. Scheinberg is an advisor to charitable foundations and cancer centers and sits on the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a biotechnology company. Dr. Scheinberg has also served on SELLAS’ Scientific Advisory Board since 2015. From 2010-2016 he served on the board of directors of Contrafect Corporation, a publicly traded clinical-stage biotechnology company. Dr. Scheinberg holds an M.D. and a Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University School of Medicine. Dr. Scheinberg earned his undergraduate degree in Biology from Cornell University.

Alexander M.M. Eggermont is currently the Director General of Institut Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, as well as Professor of Oncology at the University Paris-Sud. He is the past Professor of Surgical Oncology and current Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam. He holds the honorary Chair of Surgical Oncology at the Catholic University of Louvain, Belgium. Prof. Eggermont is a past President of the European Cancer Organisation and European Organisation for Research and Treatment of Cancer (EORTC) and past Chair of the EORTC Melanoma Group. He is the current President of the European Academy of Cancer Sciences, the chairman of Cancer Core Europe and Chair of the International Jury for Comprehensive Cancer Centre Program in Germany, as well as board member of the European Society for Medical Oncology. He obtained his MD at the University of Amsterdam and PhD in tumor immunology at the Erasmus University in Rotterdam, both in the Netherlands, and was a Fellow of the NCI Surgery Branch in Bethesda, MD, USA. He has published more than 800 peer reviewed publications.

Guenther Koehne, MD, PhD is Chief of Bone Marrow Transplantation and Hematologic Oncology at the Miami Cancer Institute, part of Baptist Health South Florida. Prior to assuming this role in mid-2017, he was an Attending Physician of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center (MSKCC) and also held the position of Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at MSKCC since 2010. He was Associate Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service at MSKCC from 2007 to 2014.

He is Associate Professor of Medicine of the Weill Cornell Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. Dr. Koehne has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients.

Dr. Koehne graduated with his Medical Degree in 1991 from the Medical University of Hamburg in Germany, and received his PhD from the same institution in 1996. He completed residencies at the Medical University of Hamburg General Hospital and Rush University Medical Center, before undertaking his fellowship training at MSKCC and Weill Cornell Medical College. He has been at MSKCC since 1996. Dr. Koehne is board certified in both Internal Medicine and Medical Oncology, and keeps up to date with the latest advances in his field by maintaining a professional membership with the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation.

Larry W. Kwak, MD, PhD is Cancer Center Associate Director, Translational Research & Developmental Therapeutics for the City of Hope National Medical Center, Director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute, and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine. From 2004 to 2014, Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Jane and John Justin Distinguished Chair in Leukemia Research. Prior to his role at M.D. Anderson, Dr. Kwak served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute for 12 years. His laboratory at the NCI was credited with the bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies. In 2010, Kwak was named to TIME Magazine’s TIME100 as one of the world’s 100 most influential people for his 20-year commitment to the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma. Dr. Kwak received his medical degree from Northwestern University Medical School and earned his Ph.D. in tumor cell biology there in 1984. He also completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California.

Sattva Neelapu, MD, PhD, serves as an Associate Professor of Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas M.D. Anderson Cancer Center.

Dr. Neelapu laboratory is focused on characterization of immune-regulatory mechanisms in the tumor microenvironment in patients with lymphoma and development of novel therapeutic strategies for patients with lymphoma. His research is supported and recognized by numerous awards from national and international organizations including the National Institutes of Health, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Doris Duke Charitable Foundation, and Leukemia and Lymphoma Society.

Dr. Neelapu obtained his medical degree in India and subsequently moved to the United States of America where he completed residency in Internal Medicine at Coney Island Hospital, Brooklyn, New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Dr. Javier Pinilla-Ibarz has a long track record of successfully applying immunology clinical and translational approaches to the treatment of leukemias and myelodysplastic syndromes. He is currently an associate member of the malignant hematology and immunology program and Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center, as well as an associate professor in the Department of Oncologic Sciences, University of South Florida College of Medicine, both in Tampa, FL. Dr. Pinilla-Ibarz received his MD and then PhD degrees from the University of Zaragoza, Spain. He then completed a research fellowship in Immunology at the Memorial Sloan-Kettering Cancer Center, as well as a Hematology and Oncology training at the same Institution. Dr. Pinilla-Ibarz has published more than 100 articles in the top peer-reviewed journals in his field.

Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently deputy director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 150 articles in the top peer-reviewed journals in his field.

Jedd D. Wolchok, MD, PhD is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSKCC); an associate director of the Ludwig Center for Cancer Immunotherapy at MSKCC, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSKCC. He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. He is also the co-director of the Swim Across America laboratory at MSKCC, one of the foremost immunotherapy and melanoma research groups in the country.

His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma.

Dr. Wolchok has authored numerous articles concerning DNA vaccines, cytokine biology, and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also co-editor of the journal Cytotherapy.